Two visits, one composite patient: this NU566 Unit 10 case study tracks a raised liver enzyme from first finding to probable diagnosis, showing what the interval between appointments revealed. Searches like "nu 566 unit 10 assignment example", "nu566 unit 10 sample" and "nu566 unit 10 example" land here.
A Raised ALT Across Two Visits: A Primary Care Case Study in Which the Interval Is Part of the Workup
[Student Name]
Purdue University Global
NU566: NP I - Introduction to Primary Care for the Nurse Practitioner
Unit 10 Primary Care Case Study
[Instructor Name]
[Date]
The patient is a composite; values, dates and intervals are bracketed composite values.
Part 1: Visit One, [Date]
Reason for visit. Mr. [E.], 48, a regional sales manager, brings results from a workplace wellness screening: ALT [74] U/L and AST [52] U/L. He feels well.
History. No abdominal pain, jaundice, itching, dark urine or fatigue. He drinks about twelve drinks a week, mostly beer on weekends and wine with client dinners. No injection drug use, no tattoos done outside licensed studios, no blood transfusions. Medications: none except occasional [ibuprofen]; no supplements. Family history: father with type 2 diabetes. He has gained about 10 kg over five years of travel for work.
Examination. BMI [33] kg/m2, waist [108] cm, blood pressure [136/86]. No jaundice, spider angiomas, palmar erythema or gynecomastia. Liver not felt below the ribs; no splenomegaly; no ascites.
Assessment. Mildly raised aminotransferases, less than twice the upper limit of normal, in an asymptomatic man with obesity and moderate alcohol intake. The pattern, ALT higher than AST, fits a hepatocellular process such as steatotic liver disease or viral hepatitis more than alcohol-related injury, in which AST typically exceeds ALT (Kwo et al., 2017). The diagnosis is deliberately deferred today, because the first visit cannot separate alcohol, metabolic fat and viral causes, and a staged plan can.
Why deferral is safe. He has no symptoms, no signs of chronic liver disease or cirrhosis, and the elevation is mild. He will return. Guidance on mildly abnormal liver chemistries supports a staged evaluation rather than immediate referral in this setting (Kwo et al., 2017).
Plan.
1. Reduce alcohol to no more than [a few] drinks a week for the interval.
2. Hepatitis B surface antigen and core antibody; hepatitis C antibody.
3. Lipid panel and A1C.
4. Complete blood count, for a platelet count to calculate a FIB-4 score.
5. Repeat liver panel in [ten] weeks.
6. Deferred: his vaccinations, raised as he stood to leave; to be reviewed at visit two.
Bridge: What Each Result Was Expected to Show
1. Hepatitis serologies. Question: is a viral cause present? Decision: positive results would change the diagnosis and prompt specialist referral; negative results remove viral hepatitis from the list.
2. Lipids and A1C. Question: does he have the metabolic features that define metabolic dysfunction-associated steatotic liver disease? Decision: abnormal results support that diagnosis and need their own treatment.
3. FIB-4. Question: what is his risk of advanced fibrosis? The score combines age, AST, ALT and platelet count. Decision: below 1.3 means low risk and primary care follow-up; 1.3 to 2.67 calls for elastography; above 2.67 calls for referral (Rinella et al., 2023).
4. Repeat liver panel after alcohol reduction. Question: how much of the elevation was alcohol? Decision: a clear fall with less drinking implicates alcohol as a contributor; a persistent elevation points to metabolic fat or another cause.
Part 2: Visit Two, [Date + 10 Weeks]
Interval history. He cut his drinking to about four drinks a week and has started walking at lunch. No new symptoms. He lost 2 kg.
Results against expectations.
1. Hepatitis B surface antigen negative; core antibody negative; hepatitis C antibody negative. Viral hepatitis excluded. He is not immune to hepatitis B.
2. Lipids: triglycerides [212] mg/dL, HDL [36] mg/dL. A1C [6.0] percent, in the prediabetes range.
3. Platelets [258] x 10^9/L. FIB-4, from age 48, AST 52, ALT 74 and platelets 258: 48 x 52 divided by (258 x the square root of 74), about 1.1. Low risk of advanced fibrosis (Sterling et al., 2006).
4. Repeat ALT [48] U/L, AST [34] U/L. Lower, but still above normal.
Assessment. Probable metabolic dysfunction-associated steatotic liver disease at low risk of advanced fibrosis, with alcohol as a likely contributor that has now been reduced. He meets the metabolic criteria through obesity, prediabetes, raised triglycerides and low HDL. Viral hepatitis is excluded. This assessment could not have been written at visit one: it needed the serologies, the metabolic results, the FIB-4 and the response to less alcohol.
Plan.
1. Weight: a target of [7 to 10] percent weight loss over the next year, which improves liver fat and inflammation (Rinella et al., 2023). Referral to a nutrition program.
2. Prediabetes: lifestyle program; A1C in [six] months.
3. Lipids: cardiovascular risk calculated; statin discussed, since statins are safe in steatotic liver disease and his cardiovascular risk is the greater threat.
4. Alcohol: continue at the reduced level or less.
5. Deferred item closed: hepatitis B vaccine series started today; hepatitis A immunity checked; influenza vaccine given.
6. Liver ultrasound: optional to document steatosis; not required to act on the diagnosis at low fibrosis risk.
Discussion: What the Interval Accomplished
An imaging-first workup at visit one, an ultrasound showing fatty liver, would likely have produced a label of fatty liver immediately. It would not have excluded viral hepatitis, measured fibrosis risk, tested the effect of alcohol or found his prediabetes. The interval did all four, at lower cost, and gave him time to change his drinking, which turned out to lower his ALT. The interval was not a delay; it was an experiment.
Why the Diagnosis Stays Probable
The word probable in the assessment is deliberate. No biopsy has been done, and none is needed at low fibrosis risk, but the diagnosis rests on excluding other causes and finding the metabolic features, not on direct proof. Two uncertainties remain. First, alcohol. Twelve drinks a week is below the threshold at which the new nomenclature would call his disease combined metabolic and alcohol-related, but self-report tends to underestimate intake, and the fall in his ALT after cutting back suggests alcohol mattered. If his drinking rises again, the label may need to change. Second, less common causes have not been tested: hemochromatosis, autoimmune hepatitis, Wilson disease and alpha-1 antitrypsin deficiency. With a falling ALT and a clear metabolic explanation, testing for all of them now would be low yield, but iron studies and further tests would follow if his ALT fails to fall with weight loss. Naming these limits in the note tells the next clinician what the diagnosis depends on and what would reopen it.
Next Checkpoint
Liver panel, A1C and weight in [six] months. FIB-4 repeated every [one to two] years. Referral to hepatology would follow if FIB-4 rises above 1.3 on repeat with indeterminate or high elastography, if ALT rises rather than falls with weight loss, or if any sign of chronic liver disease appears.
References
Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG clinical guideline: Evaluation of abnormal liver chemistries. American Journal of Gastroenterology, 112(1), 18-35. https://doi.org/10.1038/ajg.2016.517
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797-1835. https://doi.org/10.1097/HEP.0000000000000323
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., Sulkowski, M. S., Torriani, F. J., Dieterich, D. T., Thomas, D. L., Messinger, D., & Nelson, M. (2006). Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 43(6), 1317-1325. https://doi.org/10.1002/hep.21178
How this NU566 Unit 10 example is structured
The case study is built around time. Part one presents the first visit as it happened, ending on a plan that openly defers the diagnosis and says why deferral is safe: no symptoms, no stigmata of cirrhosis, and a patient who will return. The bridging section is the distinctive feature, a short table listing each pending result, the question it answers and the decision it will drive. Part two opens with interval history, then results against expectations, then an assessment that could not have been written at the first visit. A discussion section reflects on what the interval accomplished, comparing it with an immediate imaging-first workup. Concerns raised at visit one and deferred, here a vaccination update, are closed at visit two. The conclusion sets the next checkpoint and says which result would prompt referral to hepatology.
Get an NU566 Unit 10 example written to your instructions
Send the final-unit case, including any second-visit data released in your NU566 section, and the rubric. Written across both visits, the first case study is free and returned within 24-48h. It carries a bridging table of pending results, an assessment that changes when the data do, and every deferred concern closed. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
NU566 Unit 10 questions, answered
What if the case only provides one visit?
Check the prompt first; some sections release second-visit data later or ask you to project it. If you are asked to construct the follow-up, keep it plausible and label the invented results as composite. The discussion can then explain what the interval was designed to reveal and how different results would have changed the plan.
How should the two visits be formatted?
Usually as two dated notes, each complete in itself, with a short section between them explaining what was pending and why. Some rubrics prefer a single narrative with dated subheadings. Either way, a reader should be able to see exactly what was known at each point and how the assessment changed between them.
Does the case study need a discussion section?
Most versions do. It is where you explain why the staged approach was reasonable, what the interval accomplished, and what you would have done if a result had gone the other way. Cite the guideline that shaped the workup. The discussion is often weighted heavily because it shows the judgment behind the documentation.